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Introduction
Evidence based medicine [EBM] at bedside, a key
healthcare quality measure, refers to the compendium
for delivering optimum clinical care by balancing bene-
fit-harm-costs. EBM involves appraisal, interpretation
and implementation with adoption of beneficial inter-
ventions and de-adoption of interventions with potential
harm.
Our hypothesis from Niven et al [1] where the rever-
sal of intervention effect was not associated with timely
de-adoption, is that for a rapid change in clinical prac-
tice perceived cost [monetary or clinical harm] attributa-
ble to the intervention must be high.
Tight glucose control [TGC] and corticosteroids are
examples of nonproprietary and recombinant Activated
protein C [rt-APC] an example of proprietary interven-
tion with reversal of effect between publications, from
benefit to harm. All three interventions were part of the
Surviving Sepsis Campaign [SSC] EBM [2].
Objectives
We explored the impact of reversal of intervention effect
in septic shock trials on the adoption - de-adoption
cycle of these three interventions; hypothesis being visi-
ble ‘cost’ influences EBM.
Methods
Guy’s and St. Thomas’ NHS Foundation Trust (London,
England) is a 1,150-bed, University hospital with closed
mixed medical and surgical ICUs and an early adopter
of the SSC. Trained data collectors prospectively
recorded all ICU admissions with severe sepsis/septic
shock (SS) [2005 to 2013] into the SSC database. We
report the adoption - de-adoption cycle of the interven-
tions with effect reversal [rt-APC, corticosteroids, TGC]
or unchanged (Antibiotics < 3hours; lactate measure-
ment < 6 hours and lung protective ventilation [LPV])
over this period, relative to seminal publications for
each intervention in septic shock patients. [2] As an on-
going hospital approved audit since inception, informed
consent was waived. Data analysis was performed using
Stata v13.1 (StataCorp, LP).
Results
N = 1,150 septic shock admissions. Compliance with
intervention effect unchanged [antibiotics, lactate mea-
surement and LPV] was high [Figure 1a]. Publication of
CORTICUS [3]trial reduced steroid use, whereas with
the publication of PROWESS-SHOCK [4] study along-
side drug withdrawal stopped rt-APC use [Figure 1b].
Between the publications of Leuven-2 [5] and NICE-
SUGAR [6] studies, the population average glucose
values by quarter increased gradually from 5.7 to
7.6 mmol/L, over the study period. This was asso-
ciated with reduction in hypoglycemia incidence
[Figure 1c].
Conclusions
This descriptive analysis supports our hypothesis.
Further analysis will identify key drivers for ‘timely’
EBM beyond SSC bundle compliance.
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Figure 1 1a)No vs 1b) Reversal vs 1c) Blood Sugar.
Jones et al. Intensive Care Medicine Experimental 2015, 3(Suppl 1):A430
http://www.icm-experimental.com/content/3/S1/A430
Page 2 of 2
